Tyme Technologies announces the issuance of two new platform patents
The two patents represent the next generation of SM-88, joining tyrosine and melanin into a potentially more potent combination.
Tyme, a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, announced the US Patent and Trademark Office has issued patents, #9,585,841 (‘841) and #9,724,657 (‘657), that, individually and in combination, substantially expand the scope of intellectual property for Tyme’s pipeline.
“Tyme is focused on using a truly new perspective to solve old problems. For our immediate pipeline, these two patents represent the next generation of SM-88, joining tyrosine and melanin into what we believe will be a more potent combination,” said Steve Hoffman, Tyme’s CEO. “Equally important, both of these patents represent substantial internal and external development opportunities to create novel combinations in the battle against cancer.”
Patent ‘841 describes the process for combining tyrosine derivatives with other compounds, including melanin, as a drug delivery pathway into cancer cells. Tyrosine is the core component of Tyme’s SM-88 therapy and melanin is believed to enhance the oxidative effect of SM-88, which could be further amplified by intracellular delivery. Tyme believes both SM-88’s human clinical trials, as well as tyrosine-based products for diagnostic imaging, have demonstrated that tyrosine is highly selective to cancer cells. Future development projects could combine other drugs with tyrosine to achieve targeted delivery of additional therapeutics into the tumour.
Patent ‘657 describes a novel manufacturing technique to combine compounds under exceptional force. Tyme has demonstrated the use of this technique to combine tyrosine and melanin while maintaining the functionality of their original, separate components. ‘657 is not limited to Tyme’s current product portfolio and could be utilized with a multitude of drug combinations.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance